Initial Therapeutics
Danielle Carino's work experience begins in 2015 as a Sterile Technician at Anthem Pediatric Dentistry. In 2015, they also worked as a Dean's Office Student Assistant at UC Berkeley College of Environmental Design. In 2016, they worked as an Independent Chemistry Researcher at UC Berkeley and as a Student Assistant on the Operations Team at University of California, Berkeley, Haas School of Business. From 2018 to 2019, they were a Lab Assistant at the DNA Sequencing Facility, UC Berkeley. In 2019, they joined Natera as a Lab Associate, and later transitioned to the role of Research Associate 1 in 2021. Their most recent position is as a Research Associate II at Initial Therapeutics, which they started in February 2023.
Danielle Carino earned their Bachelor of Science degree in Chemical Biology from the University of California, Berkeley from 2015 to 2019.
This person is not in any offices
Initial Therapeutics
Initial Therapeutics is an ATP company that develops small-molecule medicines designed to prevent pathogenic protein synthesis. The company provides an approach that is differentiated from protein degradation and other interventions that recognize and tackle proteins only after they are fully formed for medical needs.